Literature DB >> 2105411

Lipid peroxidation and lung ultrastructural changes in an experimental model of leukocyte-mediated pulmonary injury.

E Borrelli1, P Giomarelli, O Chiara, A Casini, S Betti, L Sabatini, L Lorenzini, A Grossi.   

Abstract

The aim of this study was to study ultrastructural changes and lipid peroxidation in rabbits lung after massive complement activation and leukocyte aggregation. A prolonged and massive leukocyte activation was induced by intraperitoneal inoculation of zymosan suspected in paraffin. Fifteen animals (group 3) were given 0.6 g/kg of zymosan, 22 animals (group 2) received 1 g/kg, and 11 rabbits (group 1) were treated with paraffin alone and served as controls. An acute mortality rate of 40% was observed in group 3 and of 68% in group 2. Surviving animals were studied for 10 days. In these animals a marked decrease in circulating granulocytes and a progressive decline in arterial PO2 were recorded (PO2 on day 10 in group 2 animals was 51.94 +/- 4.26, p less than 0.01). Microscopic and ultrastructural evaluation revealed sequestration of granulocytes in the pulmonary microvasculature. Studies of lung homogenates demonstrated increased levels of lipid peroxide derivative malondialdehyde (group 2 rabbits, 1624 +/- 638; group 1, 795 +/- 57 pm/mg pt, p less than .001) and decreased levels of the tissue antioxidant alpha-tocopherol. The results of this study are compatible with the hypothesis of leukocyte-mediated injury through production of oxygen radicals.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2105411     DOI: 10.1007/bf02719671

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  26 in total

1.  Comparative immunochemical characterization of products of plasmin and leukocyte protease cleavage of human fibrinogen.

Authors:  E F Plow; T S Edgington
Journal:  Thromb Res       Date:  1978-04       Impact factor: 3.944

2.  Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage.

Authors:  T Sacks; C F Moldow; P R Craddock; T K Bowers; H S Jacob
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

3.  A mild, rapid, and efficient method of lipid extraction for use in determining vitamin E/lipid ratios.

Authors:  G W Burton; A Webb; K U Ingold
Journal:  Lipids       Date:  1985-01       Impact factor: 1.880

4.  Oxidant activity in expired breath of patients with adult respiratory distress syndrome.

Authors:  S R Baldwin; R H Simon; C M Grum; L H Ketai; L A Boxer; L J Devall
Journal:  Lancet       Date:  1986-01-04       Impact factor: 79.321

Review 5.  Neutrophils and the adult respiratory distress syndrome.

Authors:  R M Tate; J E Repine
Journal:  Am Rev Respir Dis       Date:  1983-09

6.  Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions.

Authors:  J C Fantone; P A Ward
Journal:  Am J Pathol       Date:  1982-06       Impact factor: 4.307

7.  Pharmacology of free radicals; recent views on their relation to inflammatory mechanisms.

Authors:  F Hertz; A Cloarec
Journal:  Life Sci       Date:  1984-02-20       Impact factor: 5.037

Review 8.  Complement-induced granulocyte aggregation: an unsuspected mechanism of disease.

Authors:  H S Jacob; P R Craddock; D E Hammerschmidt; C F Moldow
Journal:  N Engl J Med       Date:  1980-04-03       Impact factor: 91.245

9.  Pulmonary accumulation of polymorphonuclear leukocytes in the adult respiratory distress syndrome.

Authors:  J E Powe; A Short; W J Sibbald; A A Driedger
Journal:  Crit Care Med       Date:  1982-11       Impact factor: 7.598

10.  Systemic complement activation, lung injury, and products of lipid peroxidation.

Authors:  P A Ward; G O Till; J R Hatherill; T M Annesley; R G Kunkel
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

View more
  1 in total

1.  Complement fragment C3a in plasma of asphyxiated neonates.

Authors:  L Schrod; G Frauendienst-Egger; H B von Stockhausen; M Kirschfink
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.